MedTrace Logo

CHI-902 for Treatment of Social Anxiety Disorder

NCT04086342 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2020-06-04

No results posted yet for this study

Summary

No substantial clinical trials of Cannabidiol (CBD) in Social Anxiety Disorder (SAD) have yet been conducted. This randomized doubleblind, placebo-controlled trial of CBD in adults with SAD will evaluate the efficacy, tolerability and safety of CBD oil (CHI-902) in SAD. In addition, the effects of treatment with CHI-902 on the Endocannabinoid System (ECS) will be assessed by evaluating peripheral endocannabinoids (Arachidonoylethanolamide/Anandamide (AEA) and 2-Arachidonoyl glycerol (2-AG)) before and after treatment.

Conditions

Interventions

DRUG

CHI-902

A standardized cannabis extract in MCT oil administered in oral liquid (oil) form.

DRUG

Placebo

Placebo is a vehicle oil that will match CHI-902.

Sponsors & Collaborators

  • Centre for Addiction and Mental Health

    collaborator OTHER

  • McMaster University

    collaborator OTHER

  • Canopy Growth Corporation

    lead INDUSTRY

Principal Investigators

  • Mark Ware, MD · Canopy Growth Corporation

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-24
Primary Completion
2021-01-26
Completion
2021-01-26

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04086342 on ClinicalTrials.gov